ERLEADA® HAS UNRESTRICTED ACCESS
for 79% of commercial patients
72% of Medicare Part D patients*1
The information provided represents no statement, promise, or guarantee of Janssen Biotech, Inc., concerning levels of reimbursement, payment, or charge. Please consult your payer organization with regard to local or actual coverage, reimbursement policies, and determination processes. Information is subject to change without notice. Nothing herein may be construed as an endorsement, approval, recommendation, representation, or warranty of any kind by any plan or insurer referenced herein. This communication is solely the responsibility of Janssen Biotech, Inc.
*Prior authorization to label required for most plans.
MMIT = Managed Markets Insight & Technology; SPARTAN = Selective Prostate Androgen Receptor Targeting with ARN-509.
1. MMIT; October 2020.